

MAP Pharmaceuticals, Inc.  
Form 8-K/A  
December 30, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): December 30, 2008

**MAP PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-33719**  
(Commission  
File Number)

**20-0507047**  
(IRS Employer  
Identification No.)

**2400 Bayshore Parkway, Suite 200, Mountain**

**View, CA**  
(Address of Principal Executive Offices)

**94043**  
(Zip Code)

Registrant's telephone number, including area code: (650) 386-3100

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

## Edgar Filing: MAP Pharmaceuticals, Inc. - Form 8-K/A

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01. Entry into a Material Definitive Agreement.**

On December 19, 2008, MAP Pharmaceuticals, Inc. (the Company ) filed a Current Report on Form 8-K (the Original

8-K ) describing the License Agreement (the Agreement ) by and between the Company and ASTRAZENECA AB, a Swedish corporation ( AstraZeneca ), pursuant to which the Company will license to AstraZeneca rights to develop and commercialize the Company's proprietary nebulized formulation of budesonide, Unit Dose Budesonide ( UDB ), a next generation UDB therapy for the potential treatment of pediatric asthma and combination nebulization therapies. The Company is filing this Form 8-K/A to amend the Original 8-K by attaching the Agreement as an exhibit to the Original 8-K.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
10.1*	License Agreement, dated as of December 19, 2008, by and between MAP Pharmaceuticals, Inc., a Delaware corporation and ASTRAZENECA AB, a Swedish corporation.

\* Certain portions have been omitted pursuant to a confidential treatment request. Omitted information has been filed separately with the Securities and Exchange Commission.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 30, 2008

**MAP PHARMACEUTICALS, INC.**

By: /s/ Charlene A. Friedman  
Name: Charlene A. Friedman  
Title: Vice President, General Counsel and Secretary

**INDEX TO EXHIBITS FILED WITH**

**THE CURRENT REPORT ON FORM 8-K/A DATED DECEMBER 30, 2008**

<b>Exhibit No.</b>	<b>Description</b>
10.1*	License Agreement, dated as of December 19, 2008, by and between MAP Pharmaceuticals, Inc., a Delaware corporation and ASTRAZENECA AB, a Swedish corporation.

\* Certain portions have been omitted pursuant to a confidential treatment request. Omitted information has been filed separately with the Securities and Exchange Commission.